KESTRA MEDICAL TECHNOLOGIES
KMTSNASDAQTrading Snapshot
- Day Range
- $27.74 – $28.21
- 52-Week Range
- $14.30 – $30.00
- Volume
- $3.57B
- Avg Volume
- $4.50B
- Shares Outstanding
- 58.6M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $95M
- Last Q Revenue
- $29M
- P/E Ratio
- —
- P/S Ratio
- 17.5x
- EPS (TTM)
- $-2.42
- Dividend Yield
- —
Why Investors Own KMTS
- ✓High-growth profile — revenue up +54.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 38% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About KESTRA MEDICAL TECHNOLOGIES
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
This Guidewire Software Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Analysts changed ratings for GWRE, KMTS, CSQR, and STDN. See coverage details and price targets at Benzinga's analyst ratings page.
JP Morgan Initiates Coverage On Kestra Medical Techs with Overweight Rating, Announces Price Target of $30
JP Morgan analyst Robbie Marcus initiates coverage on Kestra Medical Techs (NASDAQ:KMTS) with a Overweight rating and announces Price Target of $30.
Oppenheimer Initiates Coverage On Kestra Medical Techs with Perform Rating
Oppenheimer analyst Suraj Kalia initiates coverage on Kestra Medical Techs (NASDAQ:KMTS) with a Perform rating.
BTIG Maintains Buy on Kestra Medical Techs, Raises Price Target to $32
BTIG analyst Marie Thibault maintains Kestra Medical Techs (NASDAQ:KMTS) with a Buy and raises the price target from $30 to $32.
Kestra Medical Technologies (NASDAQ:KMTS) Revenue Beat and EPS Miss Create Mixed Setup After Recent Rally
Kestra Medical Technologies beat Q4 revenue estimates at $28.64M but missed EPS forecasts with a -$0.67 loss. The stock surged 20% in the last month despite flat after-hours trading.